Dear Harold - good points. I'd only add that one should always do one's dd or at least accept the consequence. I know IMUL has been staying in the concept stage for way to long; and, as my previous posts on this thread has indicated, essentially it is starting all over again.
The only positive spin, if one has to find something good to stay in the stock - like myself [besides the fact that I am too much loss up the yin yang that IMUL has to take a number <sg>] - is that Dr Marr has been more decisive and realistic. I suppose he has no emotional attachment to ALLERVAX [note: I ve no clue if the concept behind it is a science or voodoo, but since IMUL has sponsorship before, it probably has something basis, tenuous it may be. Someone else here did a good piece by suggesting the cost of commercialization was too prohibitive,] so he is free to opt for cheaper research.
In a way, like many biotech outfits, IMUL is ill equiped to be a business enterprise. It is better to stick to research, hopfully accumulate a few valuable patents down the road and use the possibility of royalty as the profit engine.
Of course, this is quite far into the future, if the co doesn't burn thru its treasury 1st. That said, it is a quite a pioneer in using immune response as part of drug treatment regimen, so maybe it is worthy of admission <g>
rgds Bosco |
